The data is stunning. Issues raised:

1) The prohibition and sometimes criminalization of HCQ treatment

so prominent in the U.S. and the West has utterly failed.

2) The profoundly and persistently superior COVID outcomes

reported in SSA have persisted fifteen months in this pandemic.

3) The success of HCQ in treating COVID around the world and the

even better outcomes reported in SSA, suggests that other antimalarials

share HCQ's crossover efficacy against SARS-Cov-2.

4) The initial profoundly superior outcomes in SSA suggests a benefit

of atovaquone-proguanil (Malarone) administered to arriving travelers.

5) The persistent of the profoundly superior outcomes in SSA suggests

a benefit conferred by the high prevalence and usage of artemisinin in

the SSA countries.

6) A new paper on artemisinin can be found here.